Verrica Pharmaceuticals (FRA:1NE) ROCE % : -129.46% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Verrica Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Verrica Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2024 was -129.46%.

Verrica Pharmaceuticals ROCE % Historical Data

The historical data trend for Verrica Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verrica Pharmaceuticals ROCE % Chart

Verrica Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-37.01

-74.88

-92.89

-60.97

-117.76

Verrica Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-48.94	-71.33	-130.95	-117.25	-129.46

Verrica Pharmaceuticals ROCE % Calculation

Verrica Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-57.801	/	( ( (42.217 - 3.265)	+	(74.824 - 15.611) )	/ 2 )
	=	-57.801	/	( (38.952	+	59.213)	/ 2 )
	=	-57.801	/	49.0825
	=	-117.76 %

Verrica Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-66.284	/	( ( (74.824 - 15.611)	+	(61.002 - 17.816) )	/ 2 )
	=	-66.284	/	( ( 59.213	+	43.186 )	/ 2 )
	=	-66.284	/	51.1995
	=	-129.46 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Verrica Pharmaceuticals (FRA:1NE) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Verrica Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Verrica Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Verrica Pharmaceuticals (FRA:1NE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verrica Pharmaceuticals Inc (FRA:1NE) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

VRCA:USA 1NE:Germany

Address

44 West Gay Street, Suite 400, West Chester, PA, USA, 19380

Website

https://www.verrica.com

Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its lead product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a highly contagious and primarily pediatric viral skin disease, and common warts.

Verrica Pharmaceuticals (FRA:1NE) Headlines

No Headlines